Infertility. Female infertility
Conditions
Interventions
Intervention 1: Intervention group 1: Subcutaneous injection of human chorionic gonadotropin (hCG). In this group, 1500 IU of hCG will be injected subcutaneously on the day of embryo transfer. After e
Sponsors
Ardabil University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: Women aged 20 to 40 years Women with primary or secondary infertility who are candidates for frozen embryo transfer Having at least one frozen embryo of suitable quality for transfer FSH level less than 10 mIU/ml on the third day of the period Anti-Müllerian hormone (AMH) more than 1.1 ng/ml Couples using their own gametes Patients with good ovarian response
Exclusion criteria
Exclusion criteria: Structural abnormalities of the uterus or severe endometriosis affecting embryo implantation Severe chronic diseases such as uncontrolled diabetes or severe cardiovascular diseases Use of medications that interfere with human chorionic gonadotropin Having more than three previous unsuccessful treatment cycles using assisted reproductive techniques Unwillingness or inability to follow treatment protocols and scheduled timelines
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical pregnancy (presence of intrauterine gestational sac in ultrasound). Timepoint: Five weeks after embryo transfer (fifth week of pregnancy). Method of measurement: Transvaginal ultrasound for observation and confirmation of intrauterine gestational sac. | — |
Secondary
| Measure | Time frame |
|---|---|
| Embryo implantation rate. Timepoint: Two weeks after embryo transfer. Method of measurement: Blood test for beta-hCG and confirmation with transvaginal ultrasound.;Live birth. Timepoint: After completion of pregnancy. Method of measurement: Observation and documentation of live birth.;Endometrial thickness and pattern (trilaminar pattern). Timepoint: On the day of embryo transfer. Method of measurement: Transvaginal ultrasound.;Serum levels of human chorionic gonadotropin and progesterone. Timepoint: On the day of embryo transfer and days afterward. Method of measurement: Blood test.;Injection site adverse effects. Timepoint: Immediately after injection and in subsequent visits. Method of measurement: Clinical examination and patient report. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactElahe Shabanalizadeh
Ardabil University of Medical Sciences
Outcome results
None listed